Guangzhou LBP Medicine Science & Technology Co Ltd (688393) - Total Assets

Latest as of September 2025: CN¥1.31 Billion CNY ≈ $191.99 Million USD

Based on the latest financial reports, Guangzhou LBP Medicine Science & Technology Co Ltd (688393) holds total assets worth CN¥1.31 Billion CNY (≈ $191.99 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Guangzhou LBP Medicine Science & Technol cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Guangzhou LBP Medicine Science & Technology Co Ltd - Total Assets Trend (2011–2024)

This chart illustrates how Guangzhou LBP Medicine Science & Technology Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 688393 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Guangzhou LBP Medicine Science & Technology Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Guangzhou LBP Medicine Science & Technology Co Ltd's total assets of CN¥1.31 Billion consist of 50.8% current assets and 49.2% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 7.0%
Accounts Receivable CN¥247.21 Million 18.1%
Inventory CN¥84.44 Million 6.2%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥32.65 Million 2.4%
Goodwill CN¥26.46 Million 1.9%

Asset Composition Trend (2011–2024)

This chart illustrates how Guangzhou LBP Medicine Science & Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688393 company net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Guangzhou LBP Medicine Science & Technology Co Ltd's current assets represent 50.8% of total assets in 2024, a decrease from 86.6% in 2011.
  • Cash Position: Cash and equivalents constituted 7.0% of total assets in 2024, down from 20.0% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
  • Asset Diversification: The largest asset category is accounts receivable at 18.1% of total assets.

Guangzhou LBP Medicine Science & Technology Co Ltd Competitors by Total Assets

Key competitors of Guangzhou LBP Medicine Science & Technology Co Ltd based on total assets are shown below.

Company Country Total Assets
Tecan Group AG
SW:TECN
Switzerland CHF1.94 Billion
Nanosonics Ltd
AU:NAN
Australia AU$279.25 Million
SWS Hemodialysis Care Co. Ltd. A
SHG:688410
China CN¥2.06 Billion
Formosa Optical Technology Co Ltd
TWO:5312
Taiwan NT$9.15 Billion
ZEN Graphene Solutions Ltd
V:ZEN
Canada CA$16.87 Million
GETS Global Bhd
KLSE:5079
Malaysia RM400.10 Million
Ansell Ltd
AU:ANN
Australia AU$3.33 Billion
SDI Ltd
AU:SDI
Australia AU$135.84 Million

Guangzhou LBP Medicine Science & Technology Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 9.05 8.92 12.16
Quick Ratio 7.80 7.74 11.87
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥576.19 Million CN¥586.80 Million CN¥975.50 Million

Guangzhou LBP Medicine Science & Technology Co Ltd - Advanced Valuation Insights

This section examines the relationship between Guangzhou LBP Medicine Science & Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.11
Latest Market Cap to Assets Ratio 0.19
Asset Growth Rate (YoY) -2.7%
Total Assets CN¥1.36 Billion
Market Capitalization $264.25 Million USD

Valuation Analysis

Below Book Valuation: The market values Guangzhou LBP Medicine Science & Technology Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Guangzhou LBP Medicine Science & Technology Co Ltd's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)

The table below shows the annual total assets of Guangzhou LBP Medicine Science & Technology Co Ltd from 2011 to 2024.

Year Total Assets Change
2024-12-31 CN¥1.36 Billion
≈ $199.41 Million
-2.66%
2023-12-31 CN¥1.40 Billion
≈ $204.85 Million
+0.51%
2022-12-31 CN¥1.39 Billion
≈ $203.81 Million
+1.98%
2021-12-31 CN¥1.37 Billion
≈ $199.84 Million
+5.68%
2020-12-31 CN¥1.29 Billion
≈ $189.10 Million
+140.21%
2019-12-31 CN¥537.96 Million
≈ $78.72 Million
+12.88%
2018-12-31 CN¥476.56 Million
≈ $69.74 Million
+15.65%
2017-12-31 CN¥412.06 Million
≈ $60.30 Million
+15.42%
2016-12-31 CN¥357.02 Million
≈ $52.24 Million
+38.85%
2013-12-31 CN¥257.13 Million
≈ $37.63 Million
+33.98%
2012-12-31 CN¥191.92 Million
≈ $28.08 Million
+72.28%
2011-12-31 CN¥111.40 Million
≈ $16.30 Million
--

About Guangzhou LBP Medicine Science & Technology Co Ltd

SHG:688393 China Medical Instruments & Supplies
Market Cap
$264.25 Million
CN¥1.81 Billion CNY
Market Cap Rank
#15504 Global
#4548 in China
Share Price
CN¥19.30
Change (1 day)
+0.89%
52-Week Range
CN¥19.13 - CN¥34.80
All Time High
CN¥58.43
About

Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase… Read more